Jamie R. Oliver
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jamie R. Oliver has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
- Babak Givi
Department of Otolaryngology—Head and Neck Surgery NYU Langone Health New York New York USA
7 shared publications David Schreiber
Department of Radiation Oncology SUNY Downstate Brooklyn New York USA
4 shared publications- Easton Attwood
Department of Otolaryngology‐Head and Neck Surgery The University of Kansas Medical Center Kansas City Kansas USA
3 shared publications - Jennifer A. Villwock
Department of Otolaryngology—Head and Neck Surgery University of Kansas Medical Center Kansas City Kansas USA
3 shared publications Zujun Li
Department of Medical Oncology NYU Langone Health New York New York USA
3 shared publications- Andres M. Bur
Department of Otolaryngology – Head and Neck Surgery University of Kansas Medical Center Kansas City Kansas USA
2 shared publications
Latest Publications
- 6 May 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (6) , 650-653
Deep Learning‐Based Cribriform Segmentation and Automated Olfactory Fossa Depth Estimation on Sinus CT
- 6 May 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (6) , 650-653
Deep Learning‐Based Cribriform Segmentation and Automated Olfactory Fossa Depth Estimation on Sinus CT
- Open Access
- 29 April 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (6) , 643-645
Wearable Activity Data Demonstrate an Association Between Sinus Surgery and Improved Real‐World Activity
- 29 April 2026
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (6) , 643-645
Open AccessWearable Activity Data Demonstrate an Association Between Sinus Surgery and Improved Real‐World Activity
- 8 January 2026
- Published by Wiley in Head & Neck
- Vol. 48 (6) , 1510-1518
Improved Survival of HPV ‐Related Sinonasal Squamous Cell Carcinoma With Chemoradiation Treatment
Objective: Human papillomavirus‐related (HPV+) sinonasal squamous cell carcinoma (SNSCC) is associated with improved overall survival (OS) compared to similarly staged HPV‐negative SNSCC. However, data on treatment‐specific outcomes remain limited. Methods: We analyzed the National Cancer Database (NCDB) for all SNSCC cases diagnosed between 2010 and 2017 with available HPV testing data. Prognostically significant variables were identified via multivariable Cox regression. Propensity score‐matched cohorts were then created, matching HPV‐positive and HPV‐negative patients exactly by treatment modality and other significant prognostic factors. The association between HPV status and 5‐year OS was assessed across treatment strategies. Results: A total of 1697 HPV‐tested SNSCC cases were identified; 551 (32.5%) were HPV+. Multivariable Cox regression showed that HPV status, age, comorbidity score, tumor size, lymphovascular invasion, stage, and surgical margin status were significantly associated with outcomes. Within the propensity score‐matched cohort, HPV positivity was significantly associated with improved OS among patients treated with chemoradiation (HR = 0.55; 95% CI = 0.35–0.87, p = 0.01). No survival benefit was observed in patients treated with surgery alone (HR = 0.85; 95% CI = 0.35–2.04, p = 0.71), surgery with radiation (HR = 1.38; 95% CI = 0.64–3.02, p = 0.41), radiation alone (HR = 0.40; 95% CI = 0.11–1.41, p = 0.16), or in the combined group of these three treatment strategies (HR = 0.97; 95% CI = 0.57–1.62, p = 0.90). Conclusion: These findings suggest that HPV+ SNSCC may be particularly sensitive to chemoradiation. Routine HPV testing may be warranted to investigate if tailored treatment approaches focusing on chemoradiation may benefit patients with HPV+ SNSCC.
- 8 January 2026
- Published by Wiley in Head & Neck
- Vol. 48 (6) , 1510-1518
Improved Survival of HPV ‐Related Sinonasal Squamous Cell Carcinoma With Chemoradiation Treatment
Objective: Human papillomavirus‐related (HPV+) sinonasal squamous cell carcinoma (SNSCC) is associated with improved overall survival (OS) compared to similarly staged HPV‐negative SNSCC. However, data on treatment‐specific outcomes remain limited. Methods: We analyzed the National Cancer Database (NCDB) for all SNSCC cases diagnosed between 2010 and 2017 with available HPV testing data. Prognostically significant variables were identified via multivariable Cox regression. Propensity score‐matched cohorts were then created, matching HPV‐positive and HPV‐negative patients exactly by treatment modality and other significant prognostic factors. The association between HPV status and 5‐year OS was assessed across treatment strategies. Results: A total of 1697 HPV‐tested SNSCC cases were identified; 551 (32.5%) were HPV+. Multivariable Cox regression showed that HPV status, age, comorbidity score, tumor size, lymphovascular invasion, stage, and surgical margin status were significantly associated with outcomes. Within the propensity score‐matched cohort, HPV positivity was significantly associated with improved OS among patients treated with chemoradiation (HR = 0.55; 95% CI = 0.35–0.87, p = 0.01). No survival benefit was observed in patients treated with surgery alone (HR = 0.85; 95% CI = 0.35–2.04, p = 0.71), surgery with radiation (HR = 1.38; 95% CI = 0.64–3.02, p = 0.41), radiation alone (HR = 0.40; 95% CI = 0.11–1.41, p = 0.16), or in the combined group of these three treatment strategies (HR = 0.97; 95% CI = 0.57–1.62, p = 0.90). Conclusion: These findings suggest that HPV+ SNSCC may be particularly sensitive to chemoradiation. Routine HPV testing may be warranted to investigate if tailored treatment approaches focusing on chemoradiation may benefit patients with HPV+ SNSCC.
- 30 December 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (5) , 477-483
Asthma Outcomes Following Early Versus Delayed Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) often coexists with asthma. Endoscopic sinus surgery (ESS) improves asthma morbidity, but the impact of early surgery (< 6 months from diagnosis) versus later surgery (1–3 years) is unclear. We examined whether early ESS is associated with improved asthma outcomes compared with delayed surgery. Methods: We conducted a retrospective cohort study using the TriNetX Research Network, including adults with CRSwNP who underwent ESS. Patients were grouped as early surgery (≤ 6 months after diagnosis) or late surgery (1–3 years). Outcomes over 5 years included asthma diagnoses by severity, exacerbations, and medication use (long‐acting β2‐agonists [LABA], corticosteroids, biologics). Propensity score matching was performed 1:1 ( N = 3683 per group) based on demographics, baseline asthma severity, and asthma medication usage. Results: After matching, groups were well balanced. Early ESS was associated with lower risk of moderate (11.5% vs. 13.5%; odds ratio [OR] = 0.84; p = 0.012) and severe persistent asthma (6.5% vs. 8.4%; OR = 0.76; p = 0.003). Rates of mild intermittent or persistent asthma and overall new asthma diagnoses did not differ. Early surgery patients had fewer associated asthma exacerbations (6.4% vs. 8.1%; OR = 0.78; p = 0.005) and were less likely to require LABAs (23.7% vs. 29.4%; OR = 0.75; p < 0.0001), steroids (63.7% vs. 67.4%; OR = 0.85; p = 0.0009), and biologics (7.7% vs. 10.1%; OR = 0.74; p = 0.0004). Conclusion: Early ESS for CRSwNP is associated with reduced progression to moderate/severe asthma, fewer exacerbations, and lower reliance on oral steroids, LABAs, and biologics. These findings suggest early surgery may alter asthma trajectory and reduce treatment burden in CRSwNP patients.
- 30 December 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 16 (5) , 477-483
Asthma Outcomes Following Early Versus Delayed Sinus Surgery in Chronic Rhinosinusitis With Nasal Polyps
Background: Chronic rhinosinusitis with nasal polyps (CRSwNP) often coexists with asthma. Endoscopic sinus surgery (ESS) improves asthma morbidity, but the impact of early surgery (< 6 months from diagnosis) versus later surgery (1–3 years) is unclear. We examined whether early ESS is associated with improved asthma outcomes compared with delayed surgery. Methods: We conducted a retrospective cohort study using the TriNetX Research Network, including adults with CRSwNP who underwent ESS. Patients were grouped as early surgery (≤ 6 months after diagnosis) or late surgery (1–3 years). Outcomes over 5 years included asthma diagnoses by severity, exacerbations, and medication use (long‐acting β2‐agonists [LABA], corticosteroids, biologics). Propensity score matching was performed 1:1 ( N = 3683 per group) based on demographics, baseline asthma severity, and asthma medication usage. Results: After matching, groups were well balanced. Early ESS was associated with lower risk of moderate (11.5% vs. 13.5%; odds ratio [OR] = 0.84; p = 0.012) and severe persistent asthma (6.5% vs. 8.4%; OR = 0.76; p = 0.003). Rates of mild intermittent or persistent asthma and overall new asthma diagnoses did not differ. Early surgery patients had fewer associated asthma exacerbations (6.4% vs. 8.1%; OR = 0.78; p = 0.005) and were less likely to require LABAs (23.7% vs. 29.4%; OR = 0.75; p < 0.0001), steroids (63.7% vs. 67.4%; OR = 0.85; p = 0.0009), and biologics (7.7% vs. 10.1%; OR = 0.74; p = 0.0004). Conclusion: Early ESS for CRSwNP is associated with reduced progression to moderate/severe asthma, fewer exacerbations, and lower reliance on oral steroids, LABAs, and biologics. These findings suggest early surgery may alter asthma trajectory and reduce treatment burden in CRSwNP patients.
- 24 October 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1429-1432
Systemic Estrogen Therapy Is Associated With Lower Surgical Intervention Rates for Nasal Obstruction
- 24 October 2025
- Published by Wiley in International Forum of Allergy & Rhinology
- Vol. 15 (12) , 1429-1432
Systemic Estrogen Therapy Is Associated With Lower Surgical Intervention Rates for Nasal Obstruction
- 2 August 2023
- Published by Georg Thieme Verlag KG in Facial Plastic Surgery
- Vol. 39 (06) , 595-602
Septal Reconstruction: Simple to Complex
Nasal septal deviation is a frequent problem treated by otolaryngologists and facial plastic surgeons. Complete correction of the septal deformity is often essential both for straightening a crooked nose and for restoration of the nasal airway. While standard septoplasty techniques provide excellent outcomes in most patients, severe septal deformities may require treatment with more advanced maneuvers including adjacent grafting, caudal septal replacement, and even extracorporeal septoplasty. This article reviews a range of septoplasty techniques, with an emphasis on complex septal reconstruction and approaches that can be utilized to maintain keystone stability and establish a robust midline L-strut even in cases with challenging anatomy.
- 2 August 2023
- Published by Georg Thieme Verlag KG in Facial Plastic Surgery
- Vol. 39 (06) , 595-602
Septal Reconstruction: Simple to Complex
Nasal septal deviation is a frequent problem treated by otolaryngologists and facial plastic surgeons. Complete correction of the septal deformity is often essential both for straightening a crooked nose and for restoration of the nasal airway. While standard septoplasty techniques provide excellent outcomes in most patients, severe septal deformities may require treatment with more advanced maneuvers including adjacent grafting, caudal septal replacement, and even extracorporeal septoplasty. This article reviews a range of septoplasty techniques, with an emphasis on complex septal reconstruction and approaches that can be utilized to maintain keystone stability and establish a robust midline L-strut even in cases with challenging anatomy.
- 30 July 2022
- Published by Wiley in The Laryngoscope
- Vol. 132 (10) , E35-E36
Reply to “In Reference to: Non‐Squamous Cell Malignancies of the Larynx”
- 30 July 2022
- Published by Wiley in The Laryngoscope
- Vol. 132 (10) , E35-E36
Reply to “In Reference to: Non‐Squamous Cell Malignancies of the Larynx”
- 6 February 2022
- Published by Wiley in Head & Neck
- Vol. 44 (4) , 975-988
Machine learning directed sentinel lymph node biopsy in cutaneous head and neck melanoma
Background: The specificity of sentinel lymph node biopsy (SLNB) for detecting lymph node metastasis in head and neck melanoma (HNM) is low under current National Comprehensive Cancer Network (NCCN) treatment guidelines.Methods: Multiple machine learning (ML) algorithms were developed to identify HNM patients at very low risk of occult nodal metastasis using National Cancer Database (NCDB) data from 8466 clinically node negative HNM patients who underwent SLNB. SLNB performance under NCCN guidelines and ML algorithm recommendations was compared on independent test data from the NCDB (n = 2117) and an academic medical center (n = 96).Results: The top‐performing ML algorithm (AUC = 0.734) recommendations obtained significantly higher specificity compared to the NCCN guidelines in both internal (25.8% vs. 11.3%, p < 0.001) and external test populations (30.1% vs. 7.1%, p < 0.001), while achieving sensitivity >97%.Conclusion: Machine learning can identify clinically node negative HNM patients at very low risk of nodal metastasis, who may not benefit from SLNB.
- 6 February 2022
- Published by Wiley in Head & Neck
- Vol. 44 (4) , 975-988
Machine learning directed sentinel lymph node biopsy in cutaneous head and neck melanoma
Background: The specificity of sentinel lymph node biopsy (SLNB) for detecting lymph node metastasis in head and neck melanoma (HNM) is low under current National Comprehensive Cancer Network (NCCN) treatment guidelines.Methods: Multiple machine learning (ML) algorithms were developed to identify HNM patients at very low risk of occult nodal metastasis using National Cancer Database (NCDB) data from 8466 clinically node negative HNM patients who underwent SLNB. SLNB performance under NCCN guidelines and ML algorithm recommendations was compared on independent test data from the NCDB (n = 2117) and an academic medical center (n = 96).Results: The top‐performing ML algorithm (AUC = 0.734) recommendations obtained significantly higher specificity compared to the NCCN guidelines in both internal (25.8% vs. 11.3%, p < 0.001) and external test populations (30.1% vs. 7.1%, p < 0.001), while achieving sensitivity >97%.Conclusion: Machine learning can identify clinically node negative HNM patients at very low risk of nodal metastasis, who may not benefit from SLNB.
Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers
Background: Transoral robotic surgery (TORS) was approved by the Food and Drug Administration in 2009 for the treatment of oropharyngeal cancers (oropharyngeal squamous cell carcinoma [OPSCC]). This study investigated the adoption and safety of TORS.Methods: All patients who underwent TORS for OPSCC in the National Cancer Data Base from 2010 to 2016 were selected. Trends in the positive margin rate (PMR), 30‐day unplanned readmission, and early postoperative mortality were evaluated. Outcomes after TORS, nonrobotic surgery (NRS), and nonsurgical treatment were compared with matched‐pair survival analyses.Results: From 2010 to 2016, among 73,661 patients with OPSCC, 50,643 were treated nonsurgically, 18,024 were treated with NRS, and 4994 were treated with TORS. TORS utilization increased every year from 2010 (n = 363; 4.2%) to 2016 (n = 994; 8.3%). The TORS PMR for base of tongue malignancies decreased significantly over the study period (21.6% in 2010‐2011 vs 15.8% in 2015‐2016; P = .03). The TORS PMR at high‐volume centers (≥10 cases per year; 11.2%) was almost half that of low‐volume centers (P < .001). The rates of 30‐day unplanned readmission (4.1%) and 30‐day postoperative mortality (1.0%) after TORS were low and did not vary over time. High‐volume TORS centers had significantly lower rates of 30‐day postoperative mortality than low‐volume centers (0.5% vs 1.5%; P = .006). In matched‐pair analyses controlling for clinicopathologic cofactors, 30‐, 60‐, and 90‐day posttreatment mortality did not vary among patients with OPSCC treated with TORS, NRS, or nonsurgical treatment.Conclusions: TORS has become widely adopted and remains safe across the country with a very low risk of severe complications comparable to the risk with NRS. Although safety is excellent nationally, high‐volume TORS centers have superior outcomes with lower rates of positive margins and early postoperative mortality.
Transoral robotic surgery adoption and safety in treatment of oropharyngeal cancers
Background: Transoral robotic surgery (TORS) was approved by the Food and Drug Administration in 2009 for the treatment of oropharyngeal cancers (oropharyngeal squamous cell carcinoma [OPSCC]). This study investigated the adoption and safety of TORS.Methods: All patients who underwent TORS for OPSCC in the National Cancer Data Base from 2010 to 2016 were selected. Trends in the positive margin rate (PMR), 30‐day unplanned readmission, and early postoperative mortality were evaluated. Outcomes after TORS, nonrobotic surgery (NRS), and nonsurgical treatment were compared with matched‐pair survival analyses.Results: From 2010 to 2016, among 73,661 patients with OPSCC, 50,643 were treated nonsurgically, 18,024 were treated with NRS, and 4994 were treated with TORS. TORS utilization increased every year from 2010 (n = 363; 4.2%) to 2016 (n = 994; 8.3%). The TORS PMR for base of tongue malignancies decreased significantly over the study period (21.6% in 2010‐2011 vs 15.8% in 2015‐2016; P = .03). The TORS PMR at high‐volume centers (≥10 cases per year; 11.2%) was almost half that of low‐volume centers (P < .001). The rates of 30‐day unplanned readmission (4.1%) and 30‐day postoperative mortality (1.0%) after TORS were low and did not vary over time. High‐volume TORS centers had significantly lower rates of 30‐day postoperative mortality than low‐volume centers (0.5% vs 1.5%; P = .006). In matched‐pair analyses controlling for clinicopathologic cofactors, 30‐, 60‐, and 90‐day posttreatment mortality did not vary among patients with OPSCC treated with TORS, NRS, or nonsurgical treatment.Conclusions: TORS has become widely adopted and remains safe across the country with a very low risk of severe complications comparable to the risk with NRS. Although safety is excellent nationally, high‐volume TORS centers have superior outcomes with lower rates of positive margins and early postoperative mortality.
- 14 July 2020
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 164 (1) , 131-138
Socioeconomic and Racial Disparities and Survival of Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma
Objective: To investigate differences in epidemiology of oropharyngeal squamous cell carcinoma (OPSCC) with regards to human papillomavirus (HPV), race, and socioeconomic status (SES) using the National Cancer Database (NCDB).Study Design: Population‐based cohort study.Setting: Racial and socioeconomic disparities in survival of OPSCC have been previously acknowledged. However, the distribution of HPV‐related cancers and its influence on survival in conjunction with race and SES remain unclear.Subjects and Methods: All patients with OPSCC in the NCDB with known HPV status from 2010 to 2016 were included. Differences in presentation, HPV status, treatment, and outcomes were compared along racial and socioeconomic lines. Univariable and multivariable Cox regression survival analyses were performed.Results: In total, 45,940 patients met criteria. Most were male (38,038, 82.8%), older than 60 years (23,456, 51.5%), and white (40,156, 87.4%), and lived in higher median income areas (>$48,000, 28,587, 62.2%). Two‐thirds were HPV positive (31,007, 67.5%). HPV‐negative disease was significantly more common in lower SES (<$38,000, 2937, 41.5%, P <. 001) and among blacks (1784, 55.3%, P <. 001). Median follow‐up was 33 months. Five‐year overall survival was 81.3% (95% CI, 80.5%‐82.1%) and 59.6% (95% CI, 58.2%‐61.0%) in HPV‐positive and HPV‐negative groups, respectively. In univariable and multivariable analyses controlling for HPV status, age, stage, and treatment, black race (hazard ratio [HR], 1.22; 95% CI, 1.11‐1.34; P <. 001) and low SES (HR, 1.58; 95% CI, 1.45‐1.72; P <. 001) were associated with worse survival.Conclusion: Significant differences in HPV status exist between socioeconomic and racial groups, with HPV‐negative disease more common among blacks and lower SES. When controlling for HPV status, race and SES still influence outcomes in oropharyngeal cancers.
- 14 July 2020
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 164 (1) , 131-138
Socioeconomic and Racial Disparities and Survival of Human Papillomavirus–Associated Oropharyngeal Squamous Cell Carcinoma
Objective: To investigate differences in epidemiology of oropharyngeal squamous cell carcinoma (OPSCC) with regards to human papillomavirus (HPV), race, and socioeconomic status (SES) using the National Cancer Database (NCDB).Study Design: Population‐based cohort study.Setting: Racial and socioeconomic disparities in survival of OPSCC have been previously acknowledged. However, the distribution of HPV‐related cancers and its influence on survival in conjunction with race and SES remain unclear.Subjects and Methods: All patients with OPSCC in the NCDB with known HPV status from 2010 to 2016 were included. Differences in presentation, HPV status, treatment, and outcomes were compared along racial and socioeconomic lines. Univariable and multivariable Cox regression survival analyses were performed.Results: In total, 45,940 patients met criteria. Most were male (38,038, 82.8%), older than 60 years (23,456, 51.5%), and white (40,156, 87.4%), and lived in higher median income areas (>$48,000, 28,587, 62.2%). Two‐thirds were HPV positive (31,007, 67.5%). HPV‐negative disease was significantly more common in lower SES (<$38,000, 2937, 41.5%, P <. 001) and among blacks (1784, 55.3%, P <. 001). Median follow‐up was 33 months. Five‐year overall survival was 81.3% (95% CI, 80.5%‐82.1%) and 59.6% (95% CI, 58.2%‐61.0%) in HPV‐positive and HPV‐negative groups, respectively. In univariable and multivariable analyses controlling for HPV status, age, stage, and treatment, black race (hazard ratio [HR], 1.22; 95% CI, 1.11‐1.34; P <. 001) and low SES (HR, 1.58; 95% CI, 1.45‐1.72; P <. 001) were associated with worse survival.Conclusion: Significant differences in HPV status exist between socioeconomic and racial groups, with HPV‐negative disease more common among blacks and lower SES. When controlling for HPV status, race and SES still influence outcomes in oropharyngeal cancers.